Review



targetmol epigenetic inhibitors  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    TargetMol targetmol epigenetic inhibitors
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Targetmol Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/targetmol epigenetic inhibitors/product/TargetMol
    Average 94 stars, based on 15 article reviews
    targetmol epigenetic inhibitors - by Bioz Stars, 2026-05
    94/100 stars

    Images

    1) Product Images from "Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer"

    Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer

    Journal: bioRxiv

    doi: 10.64898/2026.04.16.719008

    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Figure Legend Snippet: High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Techniques Used: High Throughput Screening Assay, Drug discovery, Control



    Similar Products

    targetmol epigenetic inhibitors  (TargetMol)
    94
    TargetMol targetmol epigenetic inhibitors
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Targetmol Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/targetmol epigenetic inhibitors/product/TargetMol
    Average 94 stars, based on 1 article reviews
    targetmol epigenetic inhibitors - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    epigenetic inhibitor library  (TargetMol)
    93
    TargetMol epigenetic inhibitor library
    ( A ) Index chart of an <t>epigenetic</t> inhibitor library screened against P. vivax hypnozoites in a v3 (12-day 1-aminobenzotriazole [1-ABT]) assay. Teal circle: library, black square: DMSO, pink triangle: 200 nM nigericin. (B) Structures of epigenetic inhibitor hits which were confirmed to be active against P. vivax hypnozoites in dose–response assays; blue: histone deacetylase inhibitors.
    Epigenetic Inhibitor Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/epigenetic inhibitor library/product/TargetMol
    Average 93 stars, based on 1 article reviews
    epigenetic inhibitor library - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    380 targetmol epigenetic inhibitors  (TargetMol)
    94
    TargetMol 380 targetmol epigenetic inhibitors
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    380 Targetmol Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/380 targetmol epigenetic inhibitors/product/TargetMol
    Average 94 stars, based on 1 article reviews
    380 targetmol epigenetic inhibitors - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    kinase inhibitor library screening epigenetics drug library  (Selleck Chemicals)
    96
    Selleck Chemicals kinase inhibitor library screening epigenetics drug library
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Kinase Inhibitor Library Screening Epigenetics Drug Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/kinase inhibitor library screening epigenetics drug library/product/Selleck Chemicals
    Average 96 stars, based on 1 article reviews
    kinase inhibitor library screening epigenetics drug library - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    epigenetic inhibitors  (TargetMol)
    94
    TargetMol epigenetic inhibitors
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/epigenetic inhibitors/product/TargetMol
    Average 94 stars, based on 1 article reviews
    epigenetic inhibitors - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    epigenetic inhibitor library  (Selleck Chemicals)
    95
    Selleck Chemicals epigenetic inhibitor library
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Epigenetic Inhibitor Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/epigenetic inhibitor library/product/Selleck Chemicals
    Average 95 stars, based on 1 article reviews
    epigenetic inhibitor library - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    epigenetics pke inhibitor libraries  (TargetMol)
    91
    TargetMol epigenetics pke inhibitor libraries
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    Epigenetics Pke Inhibitor Libraries, supplied by TargetMol, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/epigenetics pke inhibitor libraries/product/TargetMol
    Average 91 stars, based on 1 article reviews
    epigenetics pke inhibitor libraries - by Bioz Stars, 2026-05
    91/100 stars
    		  Buy from Supplier
    237 small molecule inhibitors  (TargetMol)
    93
    TargetMol 237 small molecule inhibitors
    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
    237 Small Molecule Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/237 small molecule inhibitors/product/TargetMol
    Average 93 stars, based on 1 article reviews
    237 small molecule inhibitors - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Journal: bioRxiv

    Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer

    doi: 10.64898/2026.04.16.719008

    Figure Lengend Snippet: High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Article Snippet: The screening library comprised 619 compounds, including SGC epigenetic compounds, TargetMol epigenetic inhibitors, and FDA-approved oncology drugs ( ).

    Techniques: High Throughput Screening Assay, Drug discovery, Control

    ( A ) Index chart of an epigenetic inhibitor library screened against P. vivax hypnozoites in a v3 (12-day 1-aminobenzotriazole [1-ABT]) assay. Teal circle: library, black square: DMSO, pink triangle: 200 nM nigericin. (B) Structures of epigenetic inhibitor hits which were confirmed to be active against P. vivax hypnozoites in dose–response assays; blue: histone deacetylase inhibitors.

    Journal: eLife

    Article Title: A drug repurposing approach reveals targetable epigenetic pathways in Plasmodium vivax hypnozoites

    doi: 10.7554/eLife.98221

    Figure Lengend Snippet: ( A ) Index chart of an epigenetic inhibitor library screened against P. vivax hypnozoites in a v3 (12-day 1-aminobenzotriazole [1-ABT]) assay. Teal circle: library, black square: DMSO, pink triangle: 200 nM nigericin. (B) Structures of epigenetic inhibitor hits which were confirmed to be active against P. vivax hypnozoites in dose–response assays; blue: histone deacetylase inhibitors.

    Article Snippet: The Epigenetic Inhibitor library (Targetmol, cat L1200), containing 773 compounds at 10 mM, was purchased and re-plated in pintool-ready 384-well source plates with 200 μM nigericin and DMSO control wells.

    Techniques: Histone Deacetylase Assay

    High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Journal: bioRxiv

    Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer

    doi: 10.64898/2026.04.16.719008

    Figure Lengend Snippet: High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

    Article Snippet: A high-throughput drug screen was performed using a compound library consisting of 619 compounds, including 59 SGC epigenetic compounds, 380 TargetMol epigenetic inhibitors and 180 FDA-approved oncology drugs.

    Techniques: High Throughput Screening Assay, Drug discovery, Control